Cleared Traditional

K955013 - NOVA CO-OXIMETER ANALYZER

K955013 is an FDA 510(k) clearance for NOVA CO-OXIMETER ANALYZER, manufactured by Nova Biomedical Corp.. The device is a Class 2 Hematology device with product code GLY cleared through the Traditional 510(k) pathway after a 176-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1996
Decision
176d
Days
Class 2
Risk

K955013 is an FDA 510(k) clearance for the NOVA CO-OXIMETER ANALYZER. Classified as Oximeter To Measure Hemoglobin (product code GLY), Class II - Special Controls.

Submitted by Nova Biomedical Corp. (Walham, US). The FDA issued a Cleared decision on April 25, 1996 after a review of 176 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7500 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Nova Biomedical Corp. devices

FDA 510(k) Submission Details - K955013

510(k) Number K955013 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 01, 1995
Decision Date April 25, 1996
Days to Decision 176 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
63d slower than avg
Panel avg: 113d · This submission: 176d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GLY Device Classification - Class 2, Special Controls

Product Code GLY Oximeter To Measure Hemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7500
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.